Identification of circulating tumor cells captured by the FDA-cleared Parsortix
Circulating tumor cells
Liquid biopsy
Metastatic breast cancer
Parsortix® PC1 system
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
21 Aug 2024
21 Aug 2024
Historique:
received:
03
05
2024
accepted:
03
08
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
21
8
2024
Statut:
epublish
Résumé
Circulating Tumor Cells (CTCs) may serve as a non-invasive source of tumor material to investigate an individual's disease in real-time. The Parsortix
Identifiants
pubmed: 39169412
doi: 10.1186/s13046-024-03149-x
pii: 10.1186/s13046-024-03149-x
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
240Informations de copyright
© 2024. The Author(s).
Références
Poulet G, Massias J, Taly V. Liquid biopsy: general concepts. Acta Cytol. 2019;63:449–55. https://doi.org/10.1159/000499337 .
pubmed: 31091522
Costa JL, Schmitt FC. Liquid biopsy: a new tool in oncology. Acta Cytol. 2019;63:448. https://doi.org/10.1159/000501355 .
pubmed: 31266005
Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11:858–73. https://doi.org/10.1158/2159-8290.CD-20-1311 .
pubmed: 33811121
Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: a comprehensive review. Clin Genet. 2019;95:643–60. https://doi.org/10.1111/cge.13514 .
pubmed: 30671931
Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic — implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297–312. https://doi.org/10.1038/s41571-020-00457-x .
pubmed: 33473219
Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479–91. https://doi.org/10.1158/2159-8290.CD-15-1483 .
pubmed: 26969689
Paoletti C, Hayes DF. Circulating tumor cells. Adv Exp Med Biol. 2016;882:235–58. https://doi.org/10.1007/978-3-319-22909-6_10 .
pubmed: 26987538
Cherdyntseva NV, Litviakov NV, Denisov EV, Gervas PA, Cherdyntsev ES. Circulating tumor cells in breast cancer: functional heterogeneity, pathogenetic and clinical aspects. Exp Oncol. 2017;39:2–11. https://doi.org/10.31768/2312-8852.2017.39(1):2-11 .
pubmed: 28361862
Pantel K, Alix-Panabières C. Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation. J Immunother Cancer. 2022;10: e005615. https://doi.org/10.1136/jitc-2022-005615 .
pubmed: 36517082
pmcid: 9756199
Giuliano M, Giordano A, Jackson S, Hess KR, de Giorgi U, Mego M, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011;13:13. https://doi.org/10.1186/bcr2907 .
Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, et al. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Res Treat. 2015;154:563–71. https://doi.org/10.1007/s10549-015-3636-4 .
pubmed: 26573830
Harigopal M, Kowalski D, Vosoughi A. Enumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer. Expert Rev Mol Diagn. 2020;20:815–28. https://doi.org/10.1080/14737159.2020.1784009 .
pubmed: 32546017
Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12:6403–9. https://doi.org/10.1158/1078-0432.CCR-05-1769 .
pubmed: 17085652
Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218–24. https://doi.org/10.1158/1078-0432.CCR-05-2821 .
pubmed: 16857794
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91. https://doi.org/10.1056/NEJMOA040766 .
pubmed: 15317891
de Freitas AJA, Causin RL, Varuzza MB, Calfa S, Hidalgo Filho CMT, Komoto TT, et al. Liquid biopsy as a tool for the diagnosis, treatment, and monitoring of breast cancer. Int J Mol Sci. 2022;23(17):9952. https://doi.org/10.3390/IJMS23179952 .
pubmed: 36077348
pmcid: 9456236
Zhang X, Ju S, Wang X, Cong H. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. Clin Exp Med. 2019;19:271–9. https://doi.org/10.1007/s10238-019-00563-w .
pubmed: 31190187
Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57:1242–55. https://doi.org/10.1373/clinchem.2011.165068 .
pubmed: 21784769
Costa C, Dávila-Ibáñez AB. Methodology for the isolation and analysis of CTCs. Adv Exp Med Biol. 2020;1220:45–59. https://doi.org/10.1007/978-3-030-35805-1_4 .
pubmed: 32304079
Hu X, Zang X, Lv Y. Detection of circulating tumor cells: advances and critical concerns. Oncol Lett. 2021;21:422. https://doi.org/10.3892/ol.2021.12683 .
pubmed: 33850563
pmcid: 8025150
Riethdorf S, O’Flaherty L, Hille C, Pantel K. Clinical applications of the cell search platform in cancer patients. Adv Drug Deliv Rev. 2018;125:102–21. https://doi.org/10.1016/J.ADDR.2018.01.011 .
pubmed: 29355669
Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D, et al. Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS One. 2015;10(9):e0138032.
pubmed: 26397728
pmcid: 4580600
Andree KC, van Dalum G, Terstappen LWMM. Challenges in circulating tumor cell detection by the cell search system. Mol Oncol. 2016;10:395–407. https://doi.org/10.1016/J.MOLONC.2015.12.002 .
pubmed: 26795350
Topa J, Grešner P, Żaczek AJ, Markiewicz A. Breast cancer circulating tumor cells with mesenchymal features-an unreachable target? Cell Mol Life Sci. 2022;79:79. https://doi.org/10.1007/S00018-021-04064-6 .
Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012;12:12. https://doi.org/10.1186/1471-2407-12-178 .
Miller MC, Robinson PS, Wagner C, O’Shannessy DJ. The Parsortix™ cell separation system-a versatile liquid biopsy platform. Cytometry A. 2018;93:1234–9. https://doi.org/10.1002/CYTO.A.23571 .
pubmed: 30107082
pmcid: 6586069
Cohen EN, Jayachandran G, Moore RG, Cristofanilli M, Lang JE, Khoury JD, et al. A multi-center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the Parsortix® PC1 system. Cancers (Basel). 2022;14: 5238. https://doi.org/10.3390/CANCERS14215238 .
pubmed: 36358657
DEN200062 Trade/Device Name: Parsortix® PC1 Device Regulation Number: 21 CFR 866.6110 Regulation Name: Circulating tumor cell enrichment device Regulatory Class: Class II Product Code: QSA Dated: September 25, 2020 Received: September 28, 2020 n.d.
Breast cancer facts & figures 2019–2020. 2020. https://doi.org/10.1007/174_2016_83 .
Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106:1624–33. https://doi.org/10.1002/cncr.21778 .
pubmed: 16518827
Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, et al. Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol. 2015;143:471–8. https://doi.org/10.1309/AJCPYO5FSV3UPEXS .
pubmed: 25779997
Piñeiro R, Martínez-Pena I, López-López R. Relevance of CTC clusters in breast cancer metastasis. Adv Exp Med Biol. 2020;1220:93–115. https://doi.org/10.1007/978-3-030-35805-1_7 .
pubmed: 32304082
Jin L, Zhao W, Zhang J, Chen W, Xie T, Wang L, et al. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter® CTC capture system in patients with breast cancer. Cancer Med. 2020;9:1638–47. https://doi.org/10.1002/cam4.2825 .
pubmed: 31908156
pmcid: 7050089
Seppo A, Frisova V, Ichetovkin I, Kim Y, Evans MI, Antsaklis A, et al. Detection of circulating fetal cells utilizing automated microscopy: potential for noninvasive prenatal diagnosis of chromosomal aneuploidies. Prenat Diagn. 2008;28:815–21. https://doi.org/10.1002/pd.1987 .
pubmed: 18646239
Hatt L, Brinch M, Singh R, Møller K, Lauridsen RH, Schlütter JM, et al. A new marker set that identifies fetal cells in maternal circulation with high specificity. Prenat Diagn. 2014;34:1066–72. https://doi.org/10.1002/PD.4429 .
pubmed: 24912661
Mergenthaler S, Babochkina T, Kiefer V, Lapaire O, Holzgreve W, Hahn S. FISH analysis of all fetal nucleated cells in maternal whole blood: Improved specificity by the use of two Y-chromosome probes. J Histochem Cytochem. 2005;53:319–22. https://doi.org/10.1369/jhc.4A6404.2005 .
pubmed: 15750010
Amintas S, Bedel A, Moreau-Gaudry F, Boutin J, Buscail L, Merlio JP, et al. Circulating tumor cell clusters: united we stand divided we fall. Int J Mol Sci. 2020;21:21. https://doi.org/10.3390/IJMS21072653 .
Hong Y, Fang F, Zhang Q. Circulating tumor cell clusters: what we know and what we expect (review). Int J Oncol. 2016;49:2206. https://doi.org/10.3892/IJO.2016.3747 .
pubmed: 27779656
pmcid: 5117994
Herath S, Razavi Bazaz S, Monkman J, Ebrahimi Warkiani M, Richard D, O’Byrne K, et al. Circulating tumor cell clusters: insights into tumour dissemination and metastasis. Expert Rev Mol Diagn. 2020;20:1139–47. https://doi.org/10.1080/14737159.2020.1846523 .
pubmed: 33140979
Xu L, Mao X, Guo T, Chan PY, Shaw G, Hines J, et al. The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin Cancer Res. 2017;23:5112–22. https://doi.org/10.1158/1078-0432.CCR-16-3081 .
pubmed: 28615267
Grašič Kuhar C, Silvester J, Mencinger M, Ovčariček T, Čemažar M, Miceska S, et al. Association of circulating tumor cells, megakaryocytes and a high immune-inflammatory environment in metastatic breast cancer. Cancers (Basel). 2023;15:3397. https://doi.org/10.3390/CANCERS15133397/S1 .
pubmed: 37444507
Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev. 2017;36:235–48. https://doi.org/10.1007/S10555-017-9681-1 .
pubmed: 28667367
Machlus KR, Italiano JE. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol. 2013;201:785–96. https://doi.org/10.1083/jcb.201304054 .
pubmed: 23751492
pmcid: 3678154
Thon JN, Italiano JE. Platelets: production, morphology and ultrastructure. Handb Exp Pharmacol. 2012;210:3–22. https://doi.org/10.1007/978-3-642-29423-5_1 .
Scott GBD. Circulating megakaryocytes. Histopathology. 1982;6:467–75. https://doi.org/10.1111/J.1365-2559.1982.TB02743.X .
pubmed: 7118084
Bakchoul T, Marini I. Drug-associated thrombocytopenia. Hematology. 2018;2018:576–83. https://doi.org/10.1182/ASHEDUCATION-2018.1.576 .
pubmed: 30504360
pmcid: 6246020